Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05027282 · ClinicalTrials.gov registry record · NA
Safety and Effectiveness of the CLEAR + BRILLIANT TOUCH(R) Diode Laser 1440-nm and 1927-nm Combination Wavelength Treatment
A NA study of Photoaging, sponsored by Bausch Health Americas.
- Completed
- Registry status
- NA
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT05027282: Completed NA study of Photoaging, sponsored by Bausch Health Americas.
NCT05027282 is a NA study of Photoaging that has completed, run by Bausch Health Americas. The registered enrollment target is 28 participants, roughly in line with the 30-participant average among 14 other Photoaging trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05027282, a NA study of Photoaging, has completed, sponsored by Bausch Health Americas.
- COMPLETED
- Registry status
- NA
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective study of up to 30 subjects designed to assess the safety and effectiveness of a non-ablative fractional laser combination wavelength treatment for general resurfacing of photoaged skin. All study subjects will be treated on the whole face with the CLEAR + BRILLIANT TOUCH(R) 1440-nm and 1927-nm handpieces. Subjects will be treated with a consecutive series of four (4) treatments spaced 1 month apart, along with follow-up study visits at one (1) and three (3) months after final treatment.
Primary Outcome
Improvement in the appearance of at least one measurement of photoaging damage (fine wrinkles, skin texture, dyschromia/pigment, skin radiance, pore size or overall appearance), each assessed by the investigator using the quartile improvement score comparing standard 2D baseline photograph captured via Canfield VISIA CA system. The Quartile Improvement Score ranges from 0 to 4, with 0 = 0%, 1 = 1% to 25%, 2 = 26% to 50%, 3 = 51% to 75%, and 4 = 76% to 100% improvement. Higher scores indicated gr
Conditions Studied
Interventions
- DEVICE CLEAR + BRILLIANT TOUCH(R) 1440-nm and 1927-nm handpieces.
Study Locations (1)
Texas
- Bausch Site 001 - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2021-10-27 |
| Est. Completion | 2022-11-18 |
| Phase | NA |
What the finished NCT05027282 record still lists
NCT05027282 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, roughly in line with the 30-participant average among 14 other Photoaging trials with a reported enrollment target.
The record links to 1 condition, with Photoaging appearing as the primary indexed condition, and to 1 intervention - of which CLEAR + BRILLIANT TOUCH(R) 1440-nm and 1927-nm handpieces. is the first listed.
NCT05027282 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT05027282 about?
NCT05027282 is a clinical study titled "Safety and Effectiveness of the CLEAR + BRILLIANT TOUCH(R) Diode Laser 1440-nm and 1927-nm Combination Wavelength Treatment". This is a prospective study of up to 30 subjects designed to assess the safety and effectiveness of a non-ablative fractional laser combination wavelength treatment for general resurfacing of photoaged skin. All study subjects will be treated on the whole face with the CLEAR + BRILLIANT TOUCH(R) 144...
What is the current status of trial NCT05027282?
This trial is currently completed. It is a NA study. The enrollment target is 28 participants. The study started on 2021-10-27. Estimated completion is 2022-11-18.
What conditions does trial NCT05027282 study?
This clinical trial studies the following conditions: Photoaging.
What interventions are being tested in trial NCT05027282?
The interventions under investigation include: CLEAR + BRILLIANT TOUCH(R) 1440-nm and 1927-nm handpieces. (DEVICE).
Who is sponsoring clinical trial NCT05027282?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05027282 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Photoaging
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05027282's enrollment target sits among peer trials
28 8th of 14 higher than 7 of 14 other Photoaging trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Photoaging trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Investigating Age Dependence of Fibroblast and Extracellular Matrix Responses to Cross-linked Hyaluronic Acid Filler in Human Skin
RECRUITING · NA
-
Evaluation of the Effects of a Biostimulator and Dermal Fillers for Cheek Augmentation and Contour Deficiencies
ACTIVE NOT RECRUITING · NA
-
Evaluating Procedure Pairing of a Post-Procedure Cream Versus a Comparator in Patients Treated With a Radiofrequency Microneedling for Facial Rejuvenation
COMPLETED · NA
-
Double-Blind Study Determining the Efficacy of CannaXR in Decreasing UVA Premutagenic and Photoaging Markers
COMPLETED · NA
-
A Clinical Study to Evaluate Efficacy and Safety of a Cosmetic Product in the Treatment of Facial Lines
COMPLETED · NA
-
An Exploratory Investigation of a Novel Skincare Regimen
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI